查看更多>>摘要：目的 检测tRF-31-PER8YP9LON4VD在乳腺癌患者血清中的表达水平及探讨其对乳腺癌细胞功能的影响。 方法 收集2022年4—8月南京医科大学附属肿瘤医院57例乳腺癌患者、39例乳腺良性肿瘤患者和40名正常体检者的血清，同时整理临床特征资料，通过实时荧光定量PCR（RT-qPCR）检测乳腺癌细胞株及乳腺癌患者血清中的tRF-31-PER8YP9LON4VD的表达水平；运用细胞侵袭实验、迁移实验、CCK-8增殖实验等分析tRF-31-PER8YP9LON4VD对乳腺癌细胞功能的影响。采用受试者工作特征（ROC）曲线分析血清中tRF-31-PER8YP9LON4VD在乳腺癌中的诊断效能。采用卡方检验进行tRF-31-PER8YP9LON4VD与临床特征的相关性分析。 结果 tRF-31-PER8YP9LON4VD在乳腺癌细胞株MDA-MB-231（0.50±0.22比1.00±0.01）、T-47D（0.33±0.02比1.00±0.01）和MCF-7（0.50±0.02比1.00±0.01）的tRF-31-PER8YP9LON4VD表达水平明显低于正常乳腺上皮细胞株（1.00±0.01），差异有统计学意义（P均<0.05）。tRF-31-PER8YP9LON4VD在乳腺癌患者血清中的表达水平（1.35±1.25）低于正常体检者（6.42±3.13）和乳腺良性肿瘤患者（9.57±2.11）血清中的表达水平，差异有统计学意义（P均<0.001）。与对照组比较，过表达tRF-31-PER8YP9LON4VD的T-47D（86.67±12.22比532.00±22.68，P<0.001）和MDA-MB-231（535.33±99.12比1 055.67±24.00，P=0.002）侵袭能力较弱，T-47D（442.67±81.79比1 210.67±115.02，P=0.002）和MDA-MB-231（278.67±108.40比571.33±95.37，P=0.015）迁移能力较弱，T-47D和MDA-MB-231增殖能力较弱，差异有统计学意义（P均<0.05）。血清中tRF-31-PER8YP9LON4VD对乳腺癌诊断效能的曲线下面积0.743（95%CI 0.644~0.842），敏感度和特异度分别为89.50%和53.10%。 结论 tRF-31-PER8YP9LON4VD在乳腺癌患者血清中呈低表达，其可能抑制乳腺癌细胞的增殖、迁移和侵袭能力。 Objective To detect the expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients and to explore its effect on the function of breast cancer cells. Methods The serums of 57 breast cancer patients, 39 breast benign tumor patients and 40 normal physical examination patients in the Affiliated Cancer Hospital of Nanjing Medical University from April to August in 2022 were collected. Real-time quantitative polymerase chain reaction(RT-qPCR) to detect the expression level of tRF-31-PER8YP9LON4VD in breast cancer cell lines and serum of breast cancer patients. Cell invasion assay, migration assay and CCK-8 proliferation assay were used to analyze the effect of tRF-31-PER8YP9LON4VD on breast cancer cell function. The receiver operating characteristic curve (ROC) curve was used to analyze the diagnostic efficacy of tRF-31-PER8YP9LON4VD in serum in breast cancer. The chi-square test was used to analyze the correlation between tRF-31-PER8YP9LON4VD and clinical features. Results The expression levels of tRF-31-PER8YP9LON4VD in breast cancer cell lines MDA-MB-231 (0.50±0.22 vs 1.00±0.01), T-47D (0.33±0.02 vs 1.00±0.01) and MCF-7 (0.50±0.02 vs 1.00±0.01) were significantly lower than those in normal mammary epithelial cell lines (1.00±0.01), and the difference was statistically significant (all P<0.05). The expression level of tRF-31-PER8YP9LON4VD in the serum of breast cancer patients (1.35±1.25) was lower than that in the serum of patients with normal physical examination (6.42±3.13) and patients with benign breast tumors (9.57±2.11), and the difference was statistically significant (bothP<0.001). Compared with the control group, the invasiveness of overexpressing tRF-31-PER8YP9LON4VD T-47D (86.67±12.22vs 532.00±22.68, P<0.001) and MDA-MB-231 (535.33±99.12vs 1 055.67±24.00, P=0.002) was weaker, and that of T-47D (442.67±81.79 vs 1 210.67±115.02, P=0.002) and MDA-MB-231 (278.67±108.40 vs 571.33±95.37, P=0.015) had weaker migration ability, and T-47D and MDA-MB-231 had weaker proliferative ability (all P<0.05). The area under the curve of serum tRF-31-PER8YP9LON4VD for the diagnostic efficacy of breast cancer was 0.743 (95%CI 0.644-0.842), and the sensitivity and specificity were 89.50% and 53.10%, respectively. Conclusion tRF-31-PER8YP9LON4VD is low expressed in the serum of breast cancer patients, and it may inhibit the proliferation, migration and invasion of breast cancer cells.
查看更多>>摘要：中华检验医学杂志2021年第44卷第5期第421-424页发表的《产单核李斯特菌侵袭性感染57例分析》一文，由于作者疏忽，基金项目有误，中文摘要后的基金项目“国家重点研发计划（2019FY101211）”应改为“国家科技基础资源调查专项（2019FY101200）”，英文摘要后的Fund program“ National Key Research and Development Program of China（2019FY101211）”应改为“Special Foundation for National Science and Technology Basic Research Program of China（2019FY101200）”。特此更正。
查看更多>>摘要：目的 基于ompK36基因GD突变，建立一种快速检测产肺炎克雷伯菌碳青霉烯酶的肺炎克雷伯菌（KPC-Kp）亚胺培南最低抑菌浓度（MIC）的方法。 方法 方法学建立。收集丽水市中心医院2011年3月至2019年12月的非重复肺炎克雷伯菌258株，PCR扩增膜孔蛋白ompK36基因以及碳青霉烯酶基因blaKPC、blaNDM、blaIMP、blaOXA-48并测序确认，微量肉汤稀释法检测菌株亚胺培南MIC值，建立基因型与MIC值的对应模式。基于该模式，设计建立实时荧光聚合酶链反应（RT-PCR）快速检测MIC值的方法。利用丽水市疾控中心2017—2019年收集的159株非重复肺炎克雷伯菌进一步验证。四格表计算敏感度、特异度，Kappa检验比较RT-PCR法与肉汤稀释法结果的一致性。 结果 258株肺炎克雷伯菌中，109株未携带碳青霉烯酶基因，65株携带ompK36基因GD突变，127株携带blaKPC，15株携带blaNDM，9株携带blaIMP，未检测到blaOXA-48。以肉汤稀释法为标准，肺炎克雷伯菌耐药基因与亚胺培南MIC值存在3种对应模式：4种碳青霉烯酶基因均阴性时，MIC≤1 mg/L，敏感度为100%（107/107），特异度为98.4%（125/127）；blaKPC阳性而ompK36基因GD突变阴性时，4 mg/L≤MIC≤16 mg/L，敏感度为88.2%（60/68），特异度为98.8%（164/166）；blaKPC和ompK36基因GD突变双阳性时，MIC≥32 mg/L，敏感度为96.6%（57/59），特异度为96.6%（169/175）。RT-PCR法可准确检测blaKPC、blaNDM、blaIMP、blaOXA-48基因；在产酶菌株中ompK36基因GD突变的RT-PCR结果与测序法100%一致。以丽水市疾控中心来源的159株肺炎克雷伯菌为样本，以肉汤稀释法为参照，RT-PCR检测亚胺培南MIC值在3种模式下敏感度和特异度均大于95%，Kappa值为0.971。 结论 基于ompK36基因GD突变建立的RT-PCR法有助于快速判断KPC-Kp的亚胺培南MIC值范围。 Objective To establish a rapid method to detect the minimum inhibitory concentration (MIC) of imipenem in Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) based on ompK36 gene′s GD mutation. Methods This was a methodological evaluation study. A total of 258 isolates of Klebsiella pneumoniae were collected from Lishui Municipal Central Hospital from March 2011 to December 2019. Porin gene ompK36 and carbapenemase genes blaKPC, blaNDM, blaIMP and blaOXA-48 were amplified by PCR and confirmed by sequencing. The MIC was detected and confirmed by microbroth dilution susceptibility test, and the corresponding patterns of genotype and MIC were constructed. Based on the patterns, a method for rapid detection of imipenem MIC by real-time fluorescence PCR (RT-PCR) was designed and established. The 159 isolates of non-repetitive Klebsiella pneumoniae collected by Lishui Disease Prevention and Control Center (CDC) from 2017 to 2019 were used for further verification. The sensitivity and specificity were calculated by fourfold table. Kappa test was used to compare the consistency between RT-PCR and microbroth dilution susceptibility test. Results Among 258 isolates, 109 isolates did not carry carbapenemase gene, 65 isolates carried ompK36 gene GD mutation, 127 isolates carried blaKPC, 15 isolates carried blaNDM, 9 isolates carried blaIMP, and blaOXA-48 was not detected. With mircobroth dilution susceptibility test as the standard, there were 3 corresponding patterns between the drug resistance gene and the imipenem MIC of Kp: when all the 4 carbapenemase genes were negative, MIC≤1 mg/L, the sensitivity was 100% (107/107) and the specificity was 98.4% (125/127) when blaKPC was positive and ompK36 gene GD mutation was negative, 4 mg/L≤MIC≤16 mg/L, the sensitivity was 88.2% (60/68) and the specificity was 98.8% (164/166) when blaKPC and ompK36 gene GD mutation were both positive, MIC≥32 mg/L, the sensitivity was 96.6% (57/59) and the specificity was 96.6% (169/175). RT-PCR detected blaKPC,blaNDM, blaIMP, blaOXA-48 genes accurately.The RT-PCR results of ompK36 gene GD mutation in the KPC-producing isolates were 100% consistent with the sequencing results. In the 159 isolates from Lishui CDC, the sensitivity and specificity of imipenem MIC detected by RT-PCR were higher than 95% in all 3 patterns with mircobroth dilution susceptibility test as the standard, and Kappa value was 0.971. Conclusion The RT-PCR based on ompK36 gene GD mutation was helpful to quickly determine the MIC range of imipenem in KPC-Kp.
查看更多>>摘要：患儿女，出生6 d 19 h，以“皮肤黄染3 d，发热6 h”于2023年3月31日就诊于重庆大学附属江津医院。4月1日报告血培养危急值：革兰阴性杆菌，经质谱及生化经鉴定为沙门菌属，血清型AF多价（-），Vi（-），考虑为非A~F群沙门菌。传代培养后血清凝集试验结果为：O13，23 Hz，l，w，利用16S rRNA和gyrB基因测序鉴定为肠沙门菌肠道亚种沃兴顿株，与血清学试验相符。患儿经氨苄西林舒巴坦抗感染治疗14 d后病情好转出院。沙门菌鉴定需同时进行细菌生化鉴定和血清学试验，以保证检测准确性，为临床提供可靠的病原学诊断依据。 The patient was a 6-day-and-19-hours-old girl. On March 31, 2023, she was admitted to Chongqing University JiangJin Hospital with symptoms of yellow skin staining for 3 days and fever for 6 hours. On April 1st, the Medicine Laboratory reported a critical value in blood cultures: Gram-negative bacilli, which were identified as Salmonella through mass spectrometry and biochemical tests. It was classified as non A-F group Salmonella due to negative AF and Vi serotyping results. Subsequent serum agglutination test after subculture showed O13, 23 Hz, l, w, and further results by analysis using the sequences of the 16S rRNA and gyrB genes confirmed it as Salmonella enterica subsp.enterica Serovar Worthington Strain, consistent with the serum agglutination test result. After receiving a 14-day course of Ampicillin/Sulbact treatment for infection control, the patient′s health condition improved she was discharged from the hospital. The identification of Salmonella requires simultaneous bacterial biochemical identification and serological tests ser to ensure accurate results and provide reliable basis for etiological diagnosis.
查看更多>>摘要：特发性快动眼睡眠行为障碍（iRBD）被认为是α-突触核蛋白病的前驱期，为探索α-突触核蛋白病的发病机制和早期干预提供了重要窗口。既往很多在iRBD人群进行预测疾病转化的标志物的相关研究，主要集中在临床、体液、影像领域，其中体液标志物因其对病理变化的直接反应以及良好的可及性成为颇有前景的生物标志物，这些研究涉及不同致病机制相关的物质，结果一致性较差。本文对既往iRBD患者体液标志物研究做一综述，以期为后续研究提供参考。 Isolated rapid-eye-movement sleep behavior disorder (iRBD) is considered to be a prodromal stage of α-synucleinopathies, providing an important period for investigating biomarkers of conversion risk and potentially disease-modifying intervention. Many previous studies investigating biomarkers in patients with iRBD have focused on different domains including clinical, body fluid and imaging. Due to their direct response to the pathological changes of brain and advantaged accessibility, body fluid markers have become promising potential biomarkers. These studies have involved different molecules related to different pathogenic mechanisms with poor consistency of results. In this paper, a review of previous work on body fluid markers in patients with iRBD is presented.
查看更多>>摘要：生物标志物具有重要的临床诊断价值。侧流层析技术（LFA）是基于纸层析原理发展起来的检测手段，在疾病生物标志物检测方面有着广泛应用。目前对于LFA的研究主要关注检测特异度、识别精度和灵敏度，以及疾病标志物的多重检测或多疾病的同时检测等方面。该文对LFA的系统设计、工作原理以及在疾病标志物检测中的应用研究进展进行综述，为LFA技术的进一步发展和应用提供参考。 Biomarkers is of great significance for clinical diagnosis. Lateral flow assay (LFA) is a test method which developed based on paper chromatography and has a wide range of applications in testing disease biomarkers. The current researches of LFA mainly focus on the detection specificity, precision and sensitivity, as well as multiple detection of disease markers or simultaneous detection of multiple diseases. This artical reviews the systemic design, working principles of LFA along with the application research of LFA in detecting disease markers, in order to provide reference for development and application of LFA.
查看更多>>摘要：游离DNA（cfDNA）是存在于人体细胞外液中的DNA片段，在生理或病理条件下（如妊娠、肿瘤等），cfDNA的含量变化和分子特征等使其成为疾病诊疗的生物标志物之一。随着cfDNA富集技术以及测序、质谱等检测技术的发展，cfDNA的检测已形成完整的检验流程。基于cfDNA检测的液体活检技术在临床肿瘤诊疗、产前检查中已得到广泛应用，并且在自身免疫病诊疗中展现出较大的潜力。本综述描述了cfDNA检测技术的发展和液体活检在临床方面的应用，以及cfDNA在疾病诊断和治疗中的研究进展。 Cell-free DNA (cfDNA) is the DNA fragment existing in human extracellular fluid. In specific physiological process (such as pregnancy) or pathological conditions (such as human malignancies), the contents of cfDNA in extracellular fluid will abnormally change. The contents and molecular characteristics of cfDNA make it have the potential as a kind of biomarker for diseases′ diagnosis. With the development of cfDNA detection technology such as sequencing and mass spectrometry, liquid biopsy based on cfDNA detection has been widely used in clinical tumor diagnosis, tumor treatment, prenatal examination, and research in autoimmune diseases. A systematic summary of the latest research progress in the development of cfDNA detection technology and the clinical application of liquid biopsy, as well as the research progress of cfDNA in the diagnosis and treatment of related diseases is summarized in this review.
万方数据